BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Are multiverses real? An astrophysicist explains why it depends on how you define ‘real’ - 2Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- 3I watched the buzzy new AI documentary — and left feeling both hopeful and terrified
- 4Climate engineering would alter the oceans, reshaping marine life – our new study examines each method’s risks
- 5How many ships have been attacked in the Gulf since start of Iran war?
- Woman, 60, Is Finally Traveling the World Decades After Husband’s Death Held Her Back
- Poll: 62% of Americans would oppose U.S. military action in Greenland
- Journalists killed by Israeli strike in southern Lebanon
- Find the Keys to Fruitful Venture The board: Conveying Results on Time
- Inside the alleged Russian operation to trigger anti-government protests in Angola
- Skeleton of famed musketeer possibly found in Dutch church
- How to sound like an astronaut as you follow the first human moon mission in more than half a century
- Couch Styles of 2024: What's Moving
- At least 7 dead as Israel renews attacks on Beirut and across Lebanon
